Table 4.

Survival times of patients with or without extramedullary manifestations who received allogeneic hematopoietic stem cell transplantation

Survival times of patients who received HCT	EM AML	Non-EM AML	Hazard ratio	Cox regression p-value
Event-free survival	9.8 [6.7–14.8]	10.7 [9.1–13.2]	0.98 [0.73–1.33]	0.910
Relapse-free survival	13.0 [8.2–37.5]	16.3 [12.7–20.0]	0.99 [0.72–1.38]	0.975
Overall survival	30.8 [18.2–54.2]	72.1 [48.7–103.7]	1.29 [0.93–1.80]	0.130

Survival times for AML patients with and without extramedullary manifestations (EM) that received allogeneic hematopoietic cell transplantation (HCT, n = 573, 36.20%) are shown. Survival times in months. Cox-proportional hazard models were used to obtain univariable hazard ratios. Brackets show 95%-confidence intervals